Takeda Pharmaceutical has agreed to buy the US speciality pharmaceutical company URL Pharma for US$800 M upfront plus contingent earn-out payments based on future performance. With the acquisition, Takeda will add URL’s Colcrys® (colchicine), which reported net sales of more than US$430 M in 2011, to its gout therapy portfolio.